Coherus BioSciences, Inc. (Nasdaq: CHRS) today announced that the Patent Trial and Appeal Board (“PTAB”) of the United States ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News Hot Corp. News Litigation Management Comments

AbbVie (ABBV) Reports Upadacitinib (ABT-494) Meets All Primary & Ranked Secondary Endpoints in Second Phase 3 StudySeptember 11, 2017 8:03 AM IPR Decision Disappointing for Coherus Biosciences (CHRS) But Focus Remains on Neulasta - CowenSeptember 7, 2017 1:46 PM Jefferies Reiterates Bullish View on Abbvie (ABBV) Amid 'Double Dose' of Good NewsSeptember 7, 2017 1:06 PM Coherus BioSciences Provides Update on ‘619 IPR Institution DecisionSeptember 7, 2017 11:57 AM AbbVie (ABBV) Trades at Session High as Biotech Strength Continues, IPR Review VictorySeptember 7, 2017 11:45 AM